This new EP Publication:
- Provides patient populations with key conditions causing neuropathic
pain in each of the five major European country-markets, in 2002, 2007,
and 2012
- Reports on interviews with thought-leading physicians regarding the
treatment of neuropathic pain in the five major European country-markets
- Presents expert analysis of the commercial potential and key differences
among products in development for the treatment of neuropathic pain
- Forecasts the potential value of the neuropathic pain market in each
country, by etiology and by drug class
- Reveals the critical factors driving neuropathic pain market growth
through 2012
An Opportunity to Meet Unmet Need for Therapy
By 2012, there will be more than 1.7 million individuals in the five major
European pharmaceutical markets -France, Germany, Italy, Spain, UK, -suffering
from major neuropathic pain conditions. Given this substantial patient
population, neuropathic pain has received particular attention in recent years
due to its relative resistance to conventional analgesic therapies. The
European neuropathic pain market is characterized by a particularly high level
of unmet need for effective therapeutics due to the under-utilization of
anti-depressants, the lack of opioid availability, commonly used to treat
neuropathic pain in the U.S. and certain European country-markets, but not
others. This under-utilization stems primarily from a lack of awareness about
the potential utility of these drugs in neuropathic pain treatment and concerns
about opioid addiction.
The anticonvulsant Neurontin (gabapentin) has recently experienced
significant uptake in some countries in Europe, demonstrating the magnitude of
the potential for other drugs with newer mechanisms of action. Now the product
facing generic competition in Europe, and with Pfizer' s recent NDA submission
to the US FDA for the follow-on drug pregabalin, renewed attention is being
focused on anticipated changes in the neuropathic pain market.@
Report Objectives & Methodology
In this report WWMR, Inc., provides an overview for five major conditions
causing neuropathic pain in the five major European pharmaceutical markets:
- France
- Germany
- Italy
- Spain
- UK
This report also summarizes WWMR, Inc.' s current understanding of
neuropathic pain mechanisms, and highlights promising targets for drug
development. Also discussed are new treatments already in development that offer
the promise of improved pain management of neuropathic pain in the near future.
Models representing patient populations and the commercial value (USD) of
this market in 2002, 2007, and 2012 are assessed. These models describe the
important features of key conditions causing neuropathic pain:
- Back Pain
- Diabetic Neuropathy
- Post-Herpetic Neuralgia
- Trigeminal Neuralgia
- HIV/AIDS Neuropathy
Expert analysis and commentary describing the future neuropathic pain market
are based on:
- In-depth analysis of the medical literature, including treatment review
articles, medical textbooks, epidemiology studies, and clinical studies
- Thorough review of country-specific and overall trends
- Comprehensive analysis of prescriptions written for specific conditions,
including estimations of prescription size, number of refills, and cost
- Evaluation of drugs in the neuropathic pain drug pipeline, with
conclusions on the future directions in treatment
- Interviews with leading international clinicians and researchers,
including medical directors of selected pain centers and clinicians
treating neuropathic pain
WWMR' s European Neuropathic Pain report will allow pharmaceutical and
biotechnology executives to:
- Pinpoint the specific conditions causing neuropathic pain that have high
market potential in the next 10 years
- Understand the characteristics of the unmet need in the neuropathic pain
market in Europe as well as the key differences between markets in France,
Germany, Italy, Spain, and the UK
- Compare the epidemiology and forecasted prevalence of neuropathic pain,
among the 5 major European pharmaceutical markets
- Target specific patient populations that will benefit most from drugs in
the neuropathic pain pipeline
- Anticipate upcoming competitors and product licensing opportunities
- Recognize the impact of unique market dynamics, including patent
expiration, and the potential off-label usage, on product uptake forecasts
- Develop condition-specific and country-specific forecasts for major
conditions associated with neuropathic pain
| 
View Cart
